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Abstract
Background:  Patients with refractory angina pectoris in end-stage coronary artery disease
represent a severe condition with a higher reduction of life-expectancy and quality of life as
compared to patients with stable coronary artery disease. It was the purpose of this study to
invasively re-evaluate highly symptomatic patients with formerly diagnosed refractory angina
pectoris in end-stage coronary artery disease for feasible options of myocardial revascularization.
Methods: Thirty-four Patients formerly characterized as having end stage coronary artery disease
with refractory angina pectoris were retrospectively followed for coronary interventions.
Results:  Of those 34 patients 21 (61.8%) were eventually revascularized with percutaneous
interventional revascularization (PCI). Due to complex coronary morphology (angulation, chronic
total occlusion) PCI demanded an above-average amount of time (66 ± 42 minutes, range 25–206
minutes) and materials (contrast media 247 ± 209 ml, range 50–750 ml; PCI guiding wires 2.0 ± 1.4,
range 1–6 wires). Of PCI patients 7 (33.3%) showed a new lesion as a sign of progression of
atherosclerosis. Clinical success rate with a reduction to angina class II or lower was 71.4% at 30
days. Surgery was performed in a total of8 (23.5%) patients with a clinical success rate of 62.5%.
Based on an intention-to-treat 2 patients of originally 8 (25%) demonstrated clinical success.
Mortality during follow-up (1–18 months) was 4.8% in patients who underwent PCI, 25% in patients
treated surgically and 25% in those only treated medically.
Conclusion: The majority of patients with end-stage coronary artery disease can be treated
effectively with conventional invasive treatment modalities. Therefore even though it is challenging
and demanding PCI should be considered as a first choice before experimental interventions are
considered.
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Background
Refractory angina pectoris in end-stage coronary artery
disease is characterized by severe coronary insufficiency
but only moderately impaired left ventricular function
[1]. This in comparison to other patients with stable
angina pectoris not only leads to a reduced quality of life
as a result of invalidating clinical symptoms but also to a
severe reduction of life expectancy with a mortality rate of
10 to 15% in the first year following diagnosis [2-5].
According to the definition maximal intensification of
conventional medical and invasive treatment modalities
have been ruled out as feasible options, hence these
patients represent the frontier of clinical science and skill
in the treatment of patients with coronary artery disease.
For patients with refractory angina pectoris in end-stage
coronary artery disease various alternative therapeutic
approaches are of interest and have in part been tested:
transmyocardial laser revascularization, spinal cord stim-
ulation, pharmacological und surgical sympathectomy,
gene-therapy, bone-marrow transplantation, external
counterpulsation and medical treatments long-term inter-
mittent urokinase therapy and trimetazidine [2-12]. As
these concepts of indirect revascularization, neurophysio-
logical modulation, microcirculatory and metabolic opti-
mization are more or less successful they do not tackle the
root of the problem, the impairment of conductive blood
flow at the level of the epicardial coronary arteries. Estab-
lished interventions like percutaneous coronary interven-
tions (PCI) and coronary artery bypass operation (CABG)
which restore conductive blood flow are therefore the
most effective for relieve of ischemia and symptoms. In
particular PCI but also CABG has seen improvements of
materials and skills during recent years which have led to
better immediate and long-term results and reduced the
technical limitations of revascularization.
Therefore patients who had been previously been diag-
nosed to suffer from refractory angina pectoris in end-
stage coronary artery disease were reevaluated angio-
graphically. It was the therapeutic aim of the study pre-
sented to perform primarily PCI or CABG in this high-risk
group where feasible.
Methods
Patients
For the study 34 consecutive patients were included who
had been previously successfully treated with long-term
intermittent urokinase therapy, a rheological approach
developed for the improvement of the coronary microcir-
culation [11]. All patients had fulfilled the criteria of
refractory angina pectoris in end-stage coronary artery dis-
ease prior to the beginning of long-term intermittent
urokinase therapy. Refractory angina pectoris in coronary
artery disease is defined as the persistence of stable severe
anginal symptoms grade III or IV according to the criteria
of the Canadian Cardiovascular Society [13]. Further, the
option to use an invasive revascularization procedure
such as percutaneous coronary balloon angioplasty or
aorto-coronary bypass grafting must be excluded by cardi-
ologists and cardiac surgeons on the basis of a recent cor-
onary angiogram [1]. After treatment with 500.000 i.u.
urokinase intravenously, three times a week for 12 weeks
all patients had improved clinically at least to CCS-grade
II and were further monitored in the outpatient depart-
ment for follow-up. Patients returned for renewed coro-
nary angiography as clinical symptoms had deteriorated
again to angina grade III or IV. Coronary angiography was
the first invasive procedure in our center scheduled after
treatment with long-term intermittent urokinase therapy.
This retrospective observational study was in compliance
to the principles of the Declaration of Helsinki. All
patients consented in writing to any and especially the
interventional procedures as well as to the use of data for
scientific use as part of their hospital admission. All diag-
nostic tests, treatments and interventions were, for the
individual patient, "standard care". None of the patients
involved in this study received any study specific diagnos-
tic tests or treatments. The use of retrospective data was
approved by the ethics committee of Heinrich-Heine-Uni-
versity Düsseldorf, Germany.
Coronary angiography and percutaneous intervention
Coronary angiograms were evaluated for potential culprit
lesions which could be regarded as relevant for myocar-
dial ischemia and hence for the clinical symptoms of the
patient. In all patients stress exercise testing for electrocar-
diographic signs of myocardial ischemia were performed,
in some patients additional myocardial stress-scintigra-
phy was done. These stress tests were mostly inconclusive
as almost all patients suffered form severe triple vessel dis-
ease and had limited exercise capacity due to clinical
symptoms and beta-blocker therapy. Therefore the deci-
sion to treat with PCI was mostly based on the experience
of two interventional cardiologists (FCS, MPH). Where
feasible the decision to treat surgically was made together
with cardiac surgeons.
Critical coronary lesions were classified as chronic total
occlusions, angulated lesions, and last patent vessels. As
part of the invasive work-up of these high-risk patients
PCI was usually scheduled for a second session in order to
prepare the intervention meticulously. Interventions were
performed by two interventional cardiologists (FCS,
MPH) either alone or sometimes even alternating in one
patient in case one encountered difficulties, for example
crossing a chronic total occlusion. In general 7 French
guiding catheters (Zuma™, Medtronic, St. Paul, MN, USA)
were used for optimal visualization and back-up; variousBMC Cardiovascular Disorders 2009, 9:42 http://www.biomedcentral.com/1471-2261/9/42
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PCI guiding wires, low-profile balloons and stents were
used (see also below). Angiography was performed in a
biplane technique.
Interventions were regarded as successful when the lesion
could be dilated completely or if bypass vessels could be
attached surgically. Clinical success was defined as a
reduction of clinical symptoms at least to stage II angina
pectoris for more than 30 days.
Results
Patients
Patients had a mean age of 67 ± 10 years (range 45–85
years), 11.8% were female (Table 1). Time since long-term
intermittent urokinase therapy was 26 ± 14 months
(range 5–61 months). Of the total group 91.2% presented
with coronary triple vessel disease; 82.4% had undergone
a previous coronary artery bypass operation, 25% of
whom more than one operation.
Treatment
Based on an intention-to-treat the majority of 20 (58.8%)
of the 34 patients were treated with PCI, while 6 (17.7%)
were referred to surgery. In 8 (23.5%) patients we prima-
rily did not see a reasonable and safe option for mechan-
ical revascularization and these patients were treated
medically. For persistence or progression of clinical symp-
toms 4 patients primarily treated medically, were treated
invasively later on, 2 with PCI and 1 with surgery, while 1
patient in the PCI group was switched over to the surgical
group.
Percutaneous coronary intervention
Of the total of 21 patients (61.8% of all patients) eventu-
ally treated with PCI an angulated lesion was targeted in 8
(38%), a chronic total occlusion in 6 (29%) and the last
patent vessel in 3 patients (14%) while 4 patients (19%)
presented with a lesion in a conductance vessel with a
minor interventional risk. Evaluation of the angiograms
preceding the interventional attempt demonstrated that
of the lesions eventually treated 14 were old lesions and 7
were new lesions, the latter regarded as a sign of progres-
sion of atherosclerosis. Duration of the intervention in
this high-risk group was 66 ± 42 minutes (range 25–206
minutes) as compared to the average result of 34 ± 20
minutes in 2315 patients who underwent PCI in our cath-
eterization laboratories in that year. The use of contrast
media amounted to 247 ± 209 ml (range 50–750 ml) as
compared to the average use of 182 ± 116 ml while radia-
tion was used with an exposure of 14267 ± 9573 μgy/m2
in comparison to 6987 ± 6481 μgy/m2 in the general
patient group. An average of 1.6 ± 0.9 guiding catheters
(range 1–4 guides), 2.0 ± 1.4 PCI guiding wires (range 1–
6 wires), 1.8 ± 1.0 balloons (range 1–4 balloons) and 1.6
± 1.3 stents (range 0–5 stents) were used. Of 21 lesions
treated 15 (71.4%) could be revascularized successfully.
Angulated lesions
Skillful wiring was essential for success in extremely angu-
lated stenoses. A soft wire with a core-to-tip design
(Traverse™ Guidant, Santa Clara CA, USA) was often used
for access to the coronary periphery to be later exchanged
via an over-the-wire system (either balloon or infusion
catheter) to a more stable wire (Balance Middle Weight™,
Balance Heavy Weight™ or Extrs'port™ Guidant, Santa
Clara CA, USA) for better stability. In extremely angulated
lesions a soft infusion catheter (Transit™ 2.5 F, Cordis,
Miami, FL, USA) was used for passing the wire through
the vessel. Treating these patients we developed a maneu-
ver we termed "park'n ride maneuver" (Figure 1). In
patients with an angulation of the circumflex artery <90°
it solves the problem of extreme bending plus a long tip
of the PCI guide wire ("fishing hook") necessary for enter-
ing the circumflex artery and the soft bending of the wire
of <45° plus a short tip needed to pass the wire through a
tight proximal stenosis.
In one patient a high take-off right coronary bypass could
be accessed with a 5F Multipurpose diagnostic catheter
(Cordis, Miami, FL, USA) but the 7F Multipurpose inter-
ventional catheter did not fit due to a different angulation
of the catheter. Therefore a "long'n soft glide change-over
Table 1: Patient Characteristics
Patients
n = 34
Age (yrs) 67 ± 10
Male (%) 82.2
Female (%) 11.8
Height (m) 174 ± 8
Weight (kg) 86 ± 19
Vascular risk factors
Arterial hypertension (%) 88.2
Diabetes mellitus (%) 38.2
Insulin dependent of diabetes mellitus total (%) 46.2
Previous smoking (%) 52.9
Medication
Nitrate (%) 91.2
Beta blocker (%) 88.2
Calcium antagonist (%) 55.9
Double combination therapy (%) 41.2
Triple combination therapy (%) 44.2%
Prior invasive cardiac treatment
PCI (%) 58.8
> 2 PCI of PCI total (%) 45.0
CABG (%) 82.4
> 1 CABG of CABG total (%) 25.0BMC Cardiovascular Disorders 2009, 9:42 http://www.biomedcentral.com/1471-2261/9/42
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maneuver" was developed during the procedure. The
diagnostic catheter was placed into the take-off of the right
coronary bypass and a 3 meter PCI guide wire (Balance
Middle Weight™, Guidant, Santa Clara CA, USA) was
inserted via the diagnostic catheter into the periphery of
the right coronary artery. Using an over-the-wire maneu-
ver the diagnostic catheter was the exchanged against an
interventional 7F multipurpose interventional catheter.
Advancing the catheter over the thin wire particular care
was taken to avoid loop formation of the wire in the
ascending aorta. After insertion of the interventional cath-
eter the PCI was performed in the usual fashion.
Chronic total occlusions
In chronic total occlusions stable back-up was of critical
relevance for interventional success; Amplatz Left config-
urations were often employed for the right coronary
artery. For access to the occlusion a low profile over-the-
wire balloon (1.5 × 9 mm, OTW Maverick™, Boston Scien-
tific, Maple Grove, MN, USA) was used with soft wire (Bal-
ance Middle Weight™). Passage through the chronic total
occlusion was primarily tried with hard wires (XT 100™ –
XT400™, Guidant, Santa Clara CA, USA) as tactile feel was
regarded superior to other wires. In cases where this
approach did not yield success in particular when catheter
back-up was poor more hydrophilic wires (PT Graphix
Intermediate™ Boston Scientific, Maple Grove, MN, USA
or Shinobi™, Cordis, Miami, FL, USA) were tried. In some
patients in whom the distal end of the occlusion was not
visible double injections for proper targeting of the wire
were performed (Figure 2).
Last patent vessel
In one patient with last patent vessel, large right coronary
artery venous bypass, intraaortic ballon pumping was
started prior to the procedure and was maintained for 8
hours after successful stenting of the proximal part of the
bypass. Using a "hit-and-run approach" with primary
stenting and an inflation time of 10 seconds drop of systo-
lic arterial blood pressure from 100 mmHg to 65 mmHg
could be kept to a time of 35 seconds without the use of
catecholamines.
Cardiac surgery
Complete hemodynamic work-up yielded indications for
cardiac surgery apart from CABG. One patient who had
been previously treated by us was than treated by his local
cardiologists. He was then again referred to us for further
treatment after three high-risk PCIs had failed in another
center where he had been again classified to suffer form
refractory angina pectoris. Complete work-up revealed a
progression of valvular heart disease with severe low-gra-
dient aortic stenosis (mean gradient 40 mmHg, orifice
area 0.48 cm2, left ventricular ejection fraction 21%) who
successfully underwent surgery. In another patient who
presented with severe heart failure and a left ventricular
ejection fraction of 34% it was decided to implant a resyn-
chronization device.
Outcome
Follow-up amounted to 9 ± 5 months (range 1–18
months). Based on an intention-to-treat clinical success as
defined by a reduction to angina class II or lower for more
"Park'n Ride"-Maneuver Figure 1
"Park'n Ride"-Maneuver. (a) Angulation of the circumflex 
artery <90°, early branching and tight stenosis in the proxi-
mal part of the circumflex artery. (b) Fish-hook shape of a 
Traverse™ PCI wire (bottom right) and passing of the wire 
into an atrial side branch of the circumflex artery with a 
Transit™ infusion catheter ("turn the corner"). (c) The infu-
sion catheter rests in the atrial side branch ("park") while the 
flexible fish-hook shaped wire is exchanged against a more 
stable Balance Middle Weight™ wire with a flat and short-
tipped shape ("steer"). (d) The wire is retracted into the infu-
sion catheter so that only 2–3 mm of the wire are free in the 
vascular lumen. The infusion catheter is then pulled back with 
the wire ("back-up"). As soon as the wire snaps into the 
lumen of the main vessel it is steered forward through the 
tight stenosis ("ride"). (e) After balloon inflation a stent is 
placed. (d) complete opening of the circumflex artery, no dis-
section, atrial side-branch is preserved.BMC Cardiovascular Disorders 2009, 9:42 http://www.biomedcentral.com/1471-2261/9/42
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30 days following revascularization was achieved in 38%
in the medical, in 63% in the PCI and in 83% in the sur-
gical group. After cross-over 20 of 29 patients treated inva-
sively (69%) improved clinically (Figure 3). Clinical
success was achieved in 71.4% of the 21 patients treated
with PCI and in 5 of 8 patients who underwent surgical
treatment. 3 patients died from peri-interventional com-
plications (2 after CABG, 1 after PCI). One patient died 2
months after the decision to treat medically.
One patient, a 79 year old lady in the group treated with
PCI died as an immediate consequence of the procedure.
She had a reversible scintigraphic perfusion defect of the
anterolateral wall in a territory not supplied by a bypass
with high grade stenosis of anterior descending artery
deemed as the culprit vessel. She developed intermittent
left bundle branch block already on injection of contrast
media into the left coronary artery (Figure 4). During stent
placement with an inflation time of 10 seconds she sud-
denly acquired complete atrioventricular block. Even
though the angiographic result was good and a pacemaker
lead was inserted fast via venous sheath placed at the
beginning of the procedure she hemodynamically deteri-
orated rapidly and died within hours. We have since then
changed our approach in patients with left bundle branch
block during contrast media injection as we now place a
pacemaker lead in the right ventricle before the interven-
tion. One patient primarily treated medically was referred
to coronary artery bypass operation for progressing unsta-
ble angina and died due to excessive hemorrhage presum-
Revascularization of the right coronary artery with double- injections Figure 2
Revascularization of the right coronary artery with 
double-injections. a) occluded right coronary artery, b) 
retrograde filling of the right coronary artery via injection 
into the left coronary artery, c) passage of the PCI guiding 
wire via an over-the-wire system into the periphery of the 
right coronary artery, d) verification of intraluminal wire 
placement via injection into the left coronary artery and ret-
rograde filling, e) opened right coronary artery with multiple 
dissections, f) opened right coronary artery after stent place-
ment.
Clinical success defined a reduction of clinical symptoms to  Angina Class ≤II according to the criteria of the Canadian  Cardiovascular Society for >30 days after begin of treatment  based on a) primary-intention-to-treat in the medical (n = 8),  PCI (n = 20) and surgical (n = 6) group and after b) cross- over with a medical (n = 5), PCI (n = 21) and surgical (n = 8)  group (medical to PCI n = 2; medical to surgical n = 1; PCI to  surgical n = 1) Figure 3
Clinical success defined a reduction of clinical symp-
toms to Angina Class ≤II according to the criteria of 
the Canadian Cardiovascular Society for >30 days 
after begin of treatment based on a) primary-inten-
tion-to-treat in the medical (n = 8), PCI (n = 20) and 
surgical (n = 6) group and after b) cross-over with a 
medical (n = 5), PCI (n = 21) and surgical (n = 8) 
group (medical to PCI n = 2; medical to surgical n = 
1; PCI to surgical n = 1).BMC Cardiovascular Disorders 2009, 9:42 http://www.biomedcentral.com/1471-2261/9/42
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ably as a result of excessive adhesions secondary to
previous CABG.
Discussion
The study generates 3 major findings: (a) PCI can be per-
formed effectively and safely in most patients with end-
stage coronary artery disease previously diagnosed to suf-
fer from refractory angina pectoris in end-stage coronary
artery disease, (b) the interventional approach in these
patients needs time, material and calls for interventional
techniques which are not part of the standard repertoire
and (c) new lesion formation may be responsible for
renewed clinical symptoms.
The data presented show that primary interventional suc-
cess in PCI can be achieved in almost two thirds of the
patients with refractory angina pectoris and end-stage cor-
onary artery disease. A major factor for interventional suc-
cess in this series was surely the pooled experience of two
senior cardiologists working on one case together. In par-
ticular during longer sessions or when progress slowed for
example during recanalization of a CTO one investigator
took over for some time or the rest of the procedure. The
determination and perseverance of the whole team
including assistance personnel can be derived from the
average time of PCI which exceeds by far the average val-
ues for the general population treated in our catheteriza-
tion laboratory. A major factor for a determined approach
of the team was the fact that the long history of the
patient's severe clinical symptoms was well know to the
investigators and communicated to the rest of the team
before the intervention. For example one patient prima-
rily treated medically with an ejection fraction of 16%,
angina pectoris grade III and a last patent vessel was seen
13 times at the outpatient clinic before it was decided
together with the patient to try a high-risk approach.
Apart form the duration of intervention, the differentiated
use of materials was surely another relevant factor for pri-
mary success. Differentiated use of PCI wires was essential
for entering the coronary system in patients with
extremely tortuous and angulated vessels. In particular the
use of soft materials (infusion catheter + soft wire) was
critical for access of the target vessel and passage through
the stenosis while in the next step a more rigid and stabi-
lizing wire was inserted in an over-the-wire maneuver for
save deployment of treatment devices (balloons, stents).
This approach drives up costs of the intervention in these
patients. On the other hand that clinical success seen in
these patients justifies the approach. Furthermore the
learning curve included maneuvers newly developed dur-
ing treatment of these high-risk patients. This led from the
usual step-up approach using standard material first and
then change to non-standard material to a primary top-
step start where necessary which shortened duration and
reduced use of material. Relevant was also the use of stents
in particular in patients with CTOs as it not only stabilized
the initial angiographic result but also raises the long-term
patency rate [14-16]. As CTOs still have a relatively high
rate of reocclusion we have made it a practice to follow-up
these patients angiographically after 3–6 months irrespec-
tive of clinical symptoms. Even though the primary proce-
dure was guided by clinical symptoms we feel that once a
gate-way for coronary perfusion has been opened in these
generally cirtically perfused hearts it should be kept open.
The fact that the vast majority of patients treated with PCI
could be also be improved symptomatically supports this
approach irrespective of the occurrence of restenosis as it
has been proven that the coronary lesion can be managed
interventionally and should be further treated if neces-
sary.
Interestingly one third of the patients presented with new
lesions either in native coronary arteries or in bypass ves-
sels. This has to be regarded as a sign of progression of
atherosclerosis. These findings also signify the dynamics
of myocardial perfusion and collateral formation as in the
course of time another vessel may become causative for
clinical symptoms in respect to the previous coronary sta-
tus. At the initial time of diagnosis of refractory angina
pectoris therapeutic measures may have led to a new bal-
ance of perfusion, for example as a result of symptomatic
relieve allowing for more physical activity and collateral
formation or metabolic adaptation resulting in long-term
(a) Chronic total occlusion of the right coronary artery with  vital and ischemic myocardium of the posterior wall (scintig- raphy, data not shown) Figure 4
(a) Chronic total occlusion of the right coronary 
artery with vital and ischemic myocardium of the 
posterior wall (scintigraphy, data not shown). b) Ret-
rograde filling of the right coronary artery via injection into 
the left coronary artery; note simultaneous placement of the 
catheter in the right coronary and left coronary artery 
respectively in (a) and (b). (c) PCI wire in the distal right cor-
onary artery. (d) Verification of intraluminal seating of the 
PCI wire in the right posterior descending artery with retro-
grade filling via the catheter in the left coronary artery. (e) 
Extensive dissection of the right coronary artery after bal-
loon angioplasty. (f) Complete and stable revascularization 
after stent implantation.BMC Cardiovascular Disorders 2009, 9:42 http://www.biomedcentral.com/1471-2261/9/42
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relieve after cessation of treatment as for example with
long-term intermittent urokinase therapy. Natural pro-
gression of atherosclerosis may then disturb this balance
leading to renewed symptoms. This is of particular clinical
relevance because it means that the diagnosis of "refrac-
tory angina pectoris in end-stage coronary artery disease"
is not a final one and angiographic reevaluation has
always to be considered in the course of time or when
symptoms progress.
The diagnosis of refractory angina pectoris in end-stage
coronary artery disease may have two major consequences
for the patient: a) the patient is labelled with a severe dis-
ease and b) he may be entered into experimental clinical
studies which in turn may withhold established forms of
therapy from the patient. Given the high rate of primary
success PCI in patients with formerly refractory angina
pectoris and end-stage coronary artery disease in this
study the diagnosis of this distinct clinical symptom has
to be seen critical. This was already pointed out in
another, single- center study based on data from the early
stent era where out of 117 patients referred to transmyo-
cardial laser revascularization with presumably refractory
angina pectoris 61% could be treated conventionally
(45% medical, 16% invasive) leaving only 39% who
underwent the non-established approach of transmyocar-
dial laser revascularization [17]. Therefore careful work-
up of these patients is mandated to rule out all conven-
tional options for treatment of coronary artery disease
before the diagnosis is established in the individual
patient. This includes optimized medical treatment of cor-
onary artery disease and heart failure [18] as well as con-
sideration of interventional options like PCI and CABG by
an experienced team.
A limitation of this study is that this is primarily an obser-
vational report and as such does not have the power of a
randomized study. However, a well designed randomized
study in these severely symptomatic patients might be
impossible. The therapeutic decision will nearly always
have to be done on an individual basis, and it will be dif-
ficult to control for probable placebo effects. We do not
report long-term follow up data and can thus not judge
about prognosis.
Also, the decision for a coronary intervention was made
by one or two interventional cardiologists based on their
extensive experience, and not by a multidisciplinary team.
Not all patients underwent rigorous non-invasive testing
for proving viable myocardium before the intervention.
Although it should be essential to get as many informa-
tion about myocardial viability as possible, this proofs to
be difficult in this patient population. On the one hand
these patients are highly symptomatic and any test involv-
ing exercise will show inconclusive results because of
physical limitations. On the other hand these patients
present with complex coronary artery disease with multi-
ple stenosis and presumably a more generalized limita-
tion of flow. This is frequently not visualized by SPECT.
MRI might yield additional information but was not done
in this study.
Conclusion
Labelling a patient with a severe disease like refractory
angina pectoris in end-stage coronary artery disease may
have psychological consequences for the patient. Even
though a cause-effect relationship between the cognitive
conception of severe, potentially life-threatening coronary
artery disease and the perception of intensity and fre-
quency of angina pectoris in the patient is hard to estab-
lish, it seems likely. The reduction of clinical symptoms to
grade II angina and lower in patients treated with PCI was
considerable. From the interventional perspective it
implies that a vessel critical for myocardial perfusion was
targeted. This may be true but it has to be kept in mind
though that an interventional procedure in patients with
angina pectoris in itself can have a placebo effect of over
40% [19-21]. Subsequently clinical improvement may be
a result of psychological factors involved at least in some
of our patients. We are well aware that interventions per-
formed in patients formerly classified to suffer from
refractory angina pectoris and end-stage coronary artery
disease may be more of symptomatic and psychological
value rather than of prognostic relevance. Still we con-
tinue to pursue a primarily interventional strategy for
treatment of patients with presumably refractory angina
pectoris and end-stage coronary artery disease not only for
the pathophysiological concept of myocardial ischemia
but to assure the patient of a positive therapeutic perspec-
tive. After all, patients with presumably refractory angina
pectoris and end-stage coronary artery disease suffer from
a highly symptomatic and disabling disease and usually
share with their treating physicians a long history of inva-
sive treatment: they have a right to our continuous dedi-
cation living up to the best of our energies and skills.
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